PrognomiQ, a San Mateo, CA-based healthcare company, raised $46M in funding.
The round, which brings total funding to more than $101m, was led by Bruker Corporation, with participation from Catalio Capital Management, aMoon, Fidelity Management and Research Company, T. Rowe Price Associates, Invus, Maverick Ventures, Emerson Collective and Wing VC.
The company intends to use the funds to accelerate development of its platform and its pipeline of multi-omics products for the early detection, treatment selection and monitoring of multiple cancers.
Founded in September 2020 and led by CEO Philip Ma, PrognomiQ is a healthcare company pursuing the development and commercialization of multi-omics human tests for cancer and other complex diseases. The company uses proteomics technologies, in addition to metabolomics and genomics technologies, to develop multi-omics products to improve human health.
PrognomiQ generates rich phenotypic proteomic and metabolomics information and complements this with large-scale genomics data. The resulting deep multi-omics data provides high levels of biological insights into cancer disease mechanisms, as well as into host response, and offers novel next-generation approaches to the detection and treatment selection and monitoring of some of the most complex diseases.
FinSMEs
15/03/2022